EGFR and adenocarcinoma: Gemcitabine has been covalent bonded to a number of biologically relevant ligands with binding avidity for trophic receptors like HER2/neu and EGFR that are frequently over-expressed by many carcinomas and adenocarcinomas including those affecting the breast.